LCKLSL is a competitive Annexin A2 (AnxA2) inhibitor that effectively blocks the binding of tissue plasminogen activator (tPA) to AnxA2; it inhibits plasmin generation and exhibits anti-angiogenic activity. In human retinal microvascular endothelial cells (RMVECs), LCKLSL suppresses VEGF-induced tPA activity and plasmin generation under hypoxic conditions. In vivo, LCKLSL suppresses angiogenic responses in chicken chorioallantoic membrane and murine Matrigel plug assays, significantly reducing vascular length, number of vascular branches, junctions, and end-points at a dose of 5 μg/mL.